Versatile lipid profiling by liquid chromatography–high resolution mass spectrometry using all ion fragmentation and polarity switching. Preliminary application for serum samples phenotyping related to canine mammary cancer

2013 ◽  
Vol 796 ◽  
pp. 75-83 ◽  
Author(s):  
H. Gallart-Ayala ◽  
F. Courant ◽  
S. Severe ◽  
J.-P. Antignac ◽  
F. Morio ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Liquid Chromatography ◽  
Mammary Cancer ◽  
High Resolution Mass Spectrometry ◽  
Serum Samples ◽  
Lipid Profiling ◽  
Ion Fragmentation ◽  
Polarity Switching ◽  
Preliminary Application ◽  
Resolution Mass

scholarly journals Untargeted LC-HRMS-Based Metabolomics for Searching New Biomarkers of Pancreatic Ductal Adenocarcinoma: A Pilot Study

2016 ◽  
Vol 22 (4) ◽  
pp. 348-359 ◽  
Author(s):  
Sandra Ríos Peces ◽  
Caridad Díaz Navarro ◽  
Cristina Márquez López ◽  
Octavio Caba ◽  
Cristina Jiménez-Luna ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Liquid Chromatography ◽  
High Resolution ◽  
Pancreatic Ductal Adenocarcinoma ◽  
High Resolution Mass Spectrometry ◽  
Ductal Adenocarcinoma ◽  
Serum Samples ◽  
High Resolution Mass ◽  
Dismal Prognosis ◽  
Resolution Mass

Pancreatic ductal adenocarcinoma is one of the most lethal tumors since it is usually detected at an advanced stage in which surgery and/or current chemotherapy have limited efficacy. The lack of sensitive and specific markers for diagnosis leads to a dismal prognosis. The purpose of this study is to identify metabolites in serum of pancreatic ductal adenocarcinoma patients that could be used as diagnostic biomarkers of this pathology. We used liquid chromatography–high-resolution mass spectrometry for a nontargeted metabolomics approach with serum samples from 28 individuals, including 16 patients with pancreatic ductal adenocarcinoma and 12 healthy controls. Multivariate statistical analysis, which included principal component analysis and partial least squares, revealed clear separation between the patient and control groups analyzed by liquid chromatography–high-resolution mass spectrometry using a nontargeted metabolomics approach. The metabolic analysis showed significantly lower levels of phospholipids in the serum from patients with pancreatic ductal adenocarcinoma compared with serum from controls. Our results suggest that the liquid chromatography–high-resolution mass spectrometry–based metabolomics approach provides a potent and promising tool for the diagnosis of pancreatic ductal adenocarcinoma patients using the specific metabolites identified as novel biomarkers that could be used for an earlier detection and treatment of these patients.

scholarly journals Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics

Cancers ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 1002 ◽  
Author(s):  
Ariadna Martín-Blázquez ◽  
Cristina Jiménez-Luna ◽  
Caridad Díaz ◽  
Joaquina Martínez-Galán ◽  
Jose Prados ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Liquid Chromatography ◽  
High Resolution ◽  
High Resolution Mass Spectrometry ◽  
Untargeted Metabolomics ◽  
Ductal Adenocarcinoma ◽  
Serum Samples ◽  
High Resolution Mass ◽  
Negative Electrospray Ionization ◽  
Resolution Mass

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and lethal cancers, with a 5-year survival rate of less than 5%. In fact, complete surgical resection remains the only curative treatment. However, fewer than 20% of patients are candidates for surgery at the time of presentation. Hence, there is a critical need to identify diagnostic biomarkers with potential clinical utility in this pathology. In this context, metabolomics could be a powerful tool to search for new robust biomarkers. Comparative metabolomic profiling was performed in serum samples from 59 unresectable PDAC patients and 60 healthy controls. Samples were analyzed by using an untargeted metabolomics workflow based on liquid chromatography, coupled to high-resolution mass spectrometry in positive and negative electrospray ionization modes. Univariate and multivariate analysis allowed the identification of potential candidates that were significantly altered in PDAC patients. A panel of nine candidates yielded excellent diagnostic capacities. Pathway analysis revealed four altered pathways in our patients. This study shows the potential of liquid chromatography coupled to high-resolution mass spectrometry as a diagnostic tool for PDAC. Furthermore, it identified novel robust biomarkers with excellent diagnostic capacities.

scholarly journals Serum metabolic fingerprinting of psoriasis and psoriatic arthritis patients using solid-phase microextraction—liquid chromatography—high-resolution mass spectrometry

Metabolomics ◽  
2021 ◽  
Vol 17 (7) ◽  
Author(s):  
Nikita Looby ◽  
Anna Roszkowska ◽  
Nathaly Reyes-Garcés ◽  
Miao Yu ◽  
Tomasz Bączek ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
Liquid Chromatography ◽  
Fatty Acid ◽  
Psoriatic Arthritis ◽  
Solid Phase Microextraction ◽  
High Resolution Mass Spectrometry ◽  
Solid Phase ◽  
Healthy Controls ◽  
Serum Samples ◽  
Resolution Mass

Abstract Introduction Psoriatic arthritis (PsA), an inflammatory arthritis that develops in individuals with psoriasis, is associated with reduced quality of life. Identifying biomarkers associated with development of PsA as well as with PsA disease activity may help management of psoriatic disease. Objectives To use metabolomic fingerprinting to determine potential candidate markers of disease conversion (psoriasis to PsA) and/or PsA activity. Methods A novel sample preparation protocol based on solid-phase microextraction (SPME) was used to prepare serum samples obtained from: (1) individuals with psoriasis, some of whom develop psoriatic arthritis (n = 20); (2) individuals with varying PsA activity (mild, moderate, severe; n = 10 each) and (3) healthy controls (n = 10). Metabolomic fingerprinting of the obtained extracts was performed using reversed-phase liquid chromatography coupled to high resolution mass spectrometry. Results Psoriasis patients who developed PsA had similar metabolomic profiles to patients with mild PsA and were also indistinguishable from patients with psoriasis who did not develop PsA. Elevated levels of selected long-chain fatty acids (e.g., 3-hydroxytetradecanedioic acid) that are associated with dysregulation of fatty acid metabolism, were observed in patients with severe PsA. In addition, 1,11-undecanedicarboxylic acid—an unusual fatty acid associated with peroxisomal disorders—was also identified as a classifier in PsA patients vs. healthy individuals. Furthermore, a number of different eicosanoids with either pro- or anti-inflammatory properties were detected solely in serum samples of patients with moderate and severe PsA. Conclusion A global metabolomics approach was employed to analyze the serum metabolome of patients with psoriasis, PsA, and healthy controls in order to examine potential differences in the biochemical profiles at a metabolite level. A closer examination of circulating metabolites may potentially provide markers of PsA activity.

Sign in / Sign up

Export Citation Format

Share Document